Development asset linked to Kyowa Kirin International in public FDA and regional records.
pharma · Aplastic Anemia · Advanced Hepatocellular Carcinoma
Kyowa Kirin International
KYOWA KIRIN AUSTRALIA PTY LTD
Kyowa Kirin International drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
GB HQ
1995 Founded
690 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- GB
- Founded
- 1995
- Employees
- 690
- Programs
- 15
- Drugs
- 12
- Patents
- 0
Kyowa Kirin International pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kyowa Kirin International drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
burosumab
Musculo-skeletal system (M05)Musculo-skeletal system (M05) compound in Kyowa Kirin International's portfolio. Molecular target: Fibroblast growth factor 23.
- Target
- Fibroblast growth factor 23
- Mechanism
- Fibroblast growth factor 23 inhibitor
-
Development asset linked to Kyowa Kirin International in public FDA and regional records.
-
Development asset linked to Kyowa Kirin International in public FDA and regional records.
-
mogamulizumab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Kyowa Kirin International's portfolio. Molecular target: C-C chemokine receptor type 4.
- Target
- C-C chemokine receptor type 4
- Mechanism
- C-C chemokine receptor type 4 cross-linking agent
-
US regulatory status: approved. Molecular target: C-C chemokine receptor type 4.
- Target
- C-C chemokine receptor type 4
- Mechanism
- C-C chemokine receptor type 4 cross-linking agent
-
Development asset linked to Kyowa Kirin International in public FDA and regional records.
-
saxagliptin
Alimentary tract and metabolism (A10)US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
- Target
- Dipeptidyl peptidase 4
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Kyowa Kirin International in public FDA and regional records.
-
Development asset linked to Kyowa Kirin International in public FDA and regional records.